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Background: CM1 (centrocyte/-blast marker 1) was defined 
by a mAb against concanavalin A (Con A) activated PBMC. 
It is expressed in germinal center of human tonsil and on the 
surface of activated PBMC as well as cancer cells. Recently, 
increased productions of pro-inflammatory mediators were 
detected from activated PBMC by CM1 ligation. Methods: 
However, there is a limitation to explain the exact role of 
CM1 on inflammation and its related mechanisms, since the 
identity of CM1 is still not clarified. In our previous study, we 
have already confirmed that soluble form of CM1 was pro-
duced by Raji. Therefore, we performed Q-TOF analysis after 
immunoprecipitation of concentrated Raji culture super-
natant using anti-CM1 mAbs. Results: As a result, we found 
that CM1 is identical to enolase-1(ENO1), a glycolytic en-
zyme, and we confirmed that results by silencing ENO1 using 
siRNA. It was also confirmed through competition assay be-
tween anti-CM1 and anti-ENO1 mAbs. Finally, we inves-
tigated the possible role of CM1 in inflammatory response 
and cancer. The ligation of CM1 on Raji cells with anti-CM1 
mAbs induces the extensive production of prostaglandin 
E2(PGE2). In addition, the increased activity of matrix metal-
loproteinase (MMP)-2/9 was shown in NCI-N87, stomach 
cancer cell line by CM1 stimulation. Conclusion:  CM1 is 
identical to ENO1 and it might be an important role in the 
regulation of inflammatory responses.
[Immune Network 2011;11(3):175-181]
INTRODUCTION
We have developed monoclonal antibodies against concana-
valin  A  (Con  A)-activated  PBMC.  One  of  monoclonal  anti-
bodies showed highly positive reaction in B cell area of ger-
minal  center  of  human  tonsil  by  immunochemical  staining. 
Since it is known that B cell area of germinal center is rich 
region of centrocyte/centorblast, we called the proteins recog-
nized with monoclonal antibody made by ourselves as a cen-
t r o c y t e / - b l a s t  m a r k e r  1 ( C M 1 )  ( 1 ) .  C M 1  i s  n o t  e x p r e s s e d  o n 
hematopoietic stem cells in bone marrow as well as immature 
thymocytes  and  PBMC.  But  after  activation  by  PMA/ion-
omycin, more than 90% of peripheral B lymphocytes are be-
came to CM1 positive, while 50∼60% of peripheral T lym-
phocytes are became to CM1 positive (1). Its molecular size 
was originally detected at 70 kDa of membrane proteins, but 
it turned out that soluble form of CM1 at 40∼45 kDa was 
also existed (2). With the regard of the function of CM1, it 
is thought that it is involved in the development and differ-
entiation of B cells in secondary lymphoid tissues, especially 
g e r m i n a l  c e n t e r  i n  l y m p h  n o d e s  ( 1 ) .  I n  f a c t ,  t h e  e x t e n s i v e  
apoptosis  was  found,  when  CM1  on  CD38
＋IgD
− g e r m i n a l  
center  B  cells  were  ligated  with  anti-CM1  mAb  (1).
  I n  t h e  c a s e  o f  B u r k i t t ’s  lymphoma  cell lines, Ramos and 
Raji, which have similar phenotypic profiles with normal B 
cells found in the germinal center, cell death were triggered 
by the cross-linking of CM1 on their surfaces through the de-The Cloning of CM1
Seyeon Bae, et al.
176 IMMUNE NETWORK http://www.ksimm.or.kr Volume 11 Number 3 June 2011
struction of mitochondria membrane potential and decrease 
of Bcl-2 expression (3). Increase of Fas expression was also 
found  by  the  ligation  of  CM1  with  anti-CM1  mAbs  (4). 
Recently,  expression  of  CM1  on  Epstein-Barr  Virus  (EBV) 
transformed B lymphocytes were found (5). The same as the 
results with the ligation of CM1 on germinal center B cells 
and  Burkitt’s  lymphoma  cell  lines,  the  extensive  apoptosis 
was detected by the cross-linking of CM1 expressed on and 
EBV-transformed B lymphocytes with anti-CM1 mAbs, and it 
was closely related with the increase of reactive oxygen spe-
cies (ROS) production (5). Therefore, it is thought that CM1 
can be used as a novel centrocyte marker, during the devel-
opmental process of B cells in germinal centers through the 
regulation  of  apoptosis  via  the  various  kinds  of  apoptotic 
mechanism (4). However, all of experiments were done by 
anti-CM1 mAbs without determination of the identity of CM1.
    Recently, there  is a report  regarding  the role of  CM1 on 
the pathogenesis of tumor (2). CM1 is highly expressed on 
the surfaces of stomach cancer, hepatoma and lung cancer. 
Moreover,  its  expression  level  is  correlated  with  the  malig-
nancy of each kinds of tumor. Interestingly, we observed that 
soluble form of CM1 was increased in the serum of stomach 
cancer patients (2). Even though there are several evidences 
that might be closely related the progression of tumor, it was 
impossible to explain whether those results are novel findings 
by the novel molecules, because the identity of CM1 is not 
clearly  determined  so  far.
    Therefore, we first  tried to clarify  the identity  of CM1 in 
the present study, and then we also investigated its possible 
roles on the regulation of the pathogenesis of inflammatory 
diseases  and  stomach  cancer.
MATERIALS AND METHODS
Cells
Human  tumor  cell  lines,  Raji  (Burkitt’s  lymphoma)  and 
NCI-N87 (stomach cancer) were used in this study and main-
tained in continuous log phase growth and cultured in RPMI 
1640  medium  supplemented  wit h  2  m M  L - g l u t a m i n e ,  1 0 0  
units/ml penicillin, 100μg/ml streptomycin, and 10% heat-in-
activated fetal bovine serum (FBS). Normal human keratino-
cytes cell line, HaCaT, was used as a negative control for CM1 
expression.
Production of anti-CM1 mAb
Balb/c  mice  were  immunized  with  concanavalin  A  (Con  A, 
Sigma, St Louis, MO, USA)-activated human PBMCs (1×10
7) at 
2-week  intervals  for  2  months.  Purified  splenocytes  (1×10
8) 
from spleen of immunized mice were fused with SP2/0-Ag14 
mouse  myeloma  cells  (1×10
7)  using  polyethylene  glycol 
(PEG 4000; Sigma, St Louis, MO). The culture supernatant of 
antibody  producing  hybridoma  cells  were  collected  and 
screened through the immunohistochemical staining in serial 
frozen sections of human tonsil. The isotype of anti-CM1 mAb 
was determined by enzyme immunoassay using ScreenType 
(Boehringer Mannheim, Mannheim, Germany), according to 
manufacturer’s  protocol.  Hybridoma  cell  of  culture  super-
natant, which showed a strong positive reaction with tonsil 
section,  was  selected  and  injected  into  peritoneal  cavity  of 
Balb/c  mice.  And  then  anti-CM1  monoclonal  antibody  was 
purified from ascites by protein A column. MOPC-21 (Sigma, 
S t  L o u i s ,  M O ,  U S A )  w a s  u s e d  a s  a n  i s o t y p e  c o n t r o l .
Immunoprecipitation
Human Burkitt’s lymphoma cell line, Raji was maintained in 
continuous log phase growth and cultured in serum-free cul-
ture medium (Protein-free hybridoma medium, Gibco, Grand 
Island, NY, USA) supplemented with 100 units/ml penicillin, 
and  100μg/ml  streptomycin.  Ten  liters  of  culture  super-
natants  were  10,000×  concentrated  by  ultrafiltration  using 
(Amicon,  Millipore  Corporation,  Bedford,  MA,  USA).  And 
then the proteins, which molecular weight is more than 100 
kDa  or  less  than  30  kDa,  were  removed  via  two  separate 
steps of ultrafiltration (Microcon, Millipore Corporation, Bed-
ford, MA, USA). Hundred microliter of concentrated culture 
supernatants  were  subjected  to  immnoprecipitation  using 
twenty-five  micrograms  of  anti-CM1  mAb  and  Dynabeads 
Protein G (Invitrogen Life Technologies, CA, USA). Immuno-
precipitated proteins were electrophoresed on 10% SDS-poly-
acrylamide gel.  The gel  was  subjected to silver staining kit 
(Bio-Rad,  Hercules,  CA,  USA)  according  to  manufacturer’s 
protocol and detected bands were analysed by Q-TOF Mass 
Spectrometry.
Q-TOF Mass Spectrometry (MS)
MS/MS  of  peptides  generated  by  in-gel  digestion  was  per-
formed by nano-ESI on a Q-TOF mass spectrometer (AB Sciex 
Instruments, CA, USA). The source temperature was 80
oC. A 
potential of 1 kV was applied to the precoated borosilicate 
nanoelectrospray needles (EconoTip
TM, New Objective, USA) 
in the ion source combined with a nitrogen back-pressure of 
0∼5 psi to produce a stable flow rate (10∼30 nl/min). The The Cloning of CM1
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cone voltage was 40 V. The quadrupole analyzer was used to 
select precursor ions for fragmentation in the hexapole collision 
cell. The collision gas was Ar at a pressure of 6∼7×10
−5 mbar 
and  the  collision  energy  was  20∼30  V.  Product  ions  were 
analyzed using an orthogonal TOF analyzer, fitted with a re-
flector,  a  micro-channel  plate  detector  and  a  time-to-digital 
c o n v e r t e r .  T h e  d a t a  w e r e  p r o c e s s e d  u s i n g  a n  A n a l y s t  
program.
Protein identification and sequence processing
To  identify  the  protein,  peptide  masses  from  MS/MS  were 
matched with the theoretical peptides of proteins in the NCBI 
database using MASCOT software. Also, all MS/MS spectra re-
corded on tryptic peptides derived from spot were searched 
against  protein  sequences  from  NCBInr  and  EST  sequences 
from  NCBInr  and  EST  databases  using  the  MASCOT  search 
program  (www.matrixscience.com).
Immunoblotting
Five  micrograms  of  human  enolase-1  recombinant  protein 
(Abnoba corporation, Taipei, Taiwan) were added to SDS-loa-
ding buffer (0.5 M Tris-HCl (pH 6.8), 1 M 2-ME, 10% (w/v) 
SDS, 10% (v/v) glycerol, 0.05% (w/v) bromphenol blue) and 
boiled for 10 min. The boiled samples were then loaded into 
10% polyacrylamide gels, electrophoresed and transferred to 
nitrocellulose  membranes.  Mem b r a n e s  w e r e  b l o c k e d  o v e r -
night at 4
oC in PBS containing 0.1% (v/v) Tween 20 and 5% 
(w/v) non-fat milk proteins. Blocked membranes were then 
incubated with a mouse developed anti-CM1 mAbs for over-
night at 4
oC. And then washed three times (5 min each) with 
PBS  containing  0.1%  Tween  20,  and  incubated  with  a 
HRP-conjugated anti-mouse IgG secondary Ab (1：5,000; Cell 
signaling, Danvers, MA, USA) and detected with the ECL de-
t e c t i o n  k i t  ( A m e r s h a m ,  P i s c a t a w a y ,  N J ,  U S A ) .
Measurement of prostaglandin E2 (PGE2) production 
Raji cells were stimulated with anti-CM1 mAbs (1μg/ml) at 
room temperature with gentle  rotation  for  1 hr. Cells were 
transferred into 6-well plate and incubated for indicated times 
at 37
oC in a humidified incubator containing 5% CO2 and then 
cultured for another 24 hrs. The amount of PGE2 produced 
by CM1 stimulation was measured by ELISA (Cayman, Minn-
e a p o l i s ,  M N ,  U S A ) ,  a s  m a n u f a c t u r e r’s  protocols.
siRNA transfection
H um an  E N O 1  si RN A a nd  s cr am bl ed  si RN A we re  pu rc h ase d 
from SantaCruz (Palo alto, CA, USA). Human Burkitt’s lym-
phoma  cell line,  Raji  in  exponential  phase of  growth  were 
plated in T75 flask at 3×10
6 cells/flask, then transfected with 
20, 40 nM of siRNA using effectene (QIAGEN GmbH, Hilden, 
Germany)  according  to  the  manufacturer’s  protocol.  The 
transfection  efficiency  by  RT-PCR  using  specific  primer  for 
ENO1was determined at 72 hrs after transfection. Control cells 
were  transfected  with  scrambled  siRNA.
Flow cytometric analysis
The expression of CM1 on several kinds of tumor cell lines 
was examined by flow cytometry analysis. Briefly, cells were 
washed twice with ice-cold PBS containing 0.05% BSA and 
0.02% sodium azide. After two washes, cells were incubated 
with  FITC-conjugated  anti-CM1  mAbs  or  anti-ENO1  mAbs 
(SantaCruz, Palo Alto, CA, USA) for 30 min on ice. After two 
washes, cells were acquired on an FACS Calibur (BD Biosci-
e n c e s ,  S a n  J o s e ,  C A ,  U S A ) .
Gelatin zymography
T o  e x a m i n e  t h e  a c t i v i t y  o f  m a t r i x  g e l a t i n a s e s  ( M M P - 2  a n d  
MMP-9),  tumor  cell  were  incubated  in  the  presence  or  ab-
sence of anti-ENO1 mAb, and then lysates (10μg/lane) were 
loaded onto 10% gelatin gel of 0.75 mm thickness. After elec-
trophoresis, the gel was washed with 2.5% Triton X-100 buf-
fer containing 50 mM Tris (pH 7.4) and 5 mM CaCl 2 for 1 
hr at room temperature. Following a brief wash with distilled 
water, the gel was incubated with incubation buffer contain-
ing 50 mM Tris (pH 7.5), 200 mM NaCl, and 20 mM CaCl2 
for 16 hrs at 37
oC. The gel was stained with 0.2% Coomassie 
Blue  for  1  hr,  and  then  de-stained  with  a  mixture  of  30% 
methanol and 10% acetic acid for 2 hrs. Digested regions ap-
peared  as  white  bands  on  a  blue  background.
RESULTS
Identification of CM1 by Q-Tof analysis
Two types of CM1 exist. One is 70 kDa of membranous form, 
and the other is 40∼45 kDa of soluble form. Based on the 
reports  that  Burkitt’s  lymphoma  cell  lines,  Raji  and  Ramos 
were expressed CM1 on the surface, we tried to identify CM1 
through  immunoprecipitation  using  membrane  protein  frac-
tion from Raji. However, we could not obtain clear results, 
since CM1 was not dominantly expressed on the surface of 
Raji. Based on the reports that Raji and Ramos largely pro-
duced soluble CM1 (sCM1), CM1 was immunopreciptated us-The Cloning of CM1
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Figure 1. Immunoprecipitation of CM1 with anti-CM1 mAb. Ten liters
of Raji culture supernatants were 10,000x concentrated by ultra-
filtration, and then proteins, which molecular weight is more than 100
kDa or less than 30 kDa, were cuf-off by two separate steps of 
ultrafiltration. Hundred microliter of concentrated culture supernatants
were subjected to immnoprecipitation by using twenty-five micro-
grams of anti-CM1 mAb and Dynabeads Protein G. Immunopreci-
pitated proteins were electrophoresed on 10% SDS-polyacrylamide gel
and stained by silver staining kit according to manufacturer’s protocol.
Three bands (arrow) near at 46 kDa were selected and subject to 
further investigation by Q-Tof analysis. 
Table I. Result of Q-Tof analysis
Spot Protein ID
1 gi|4503571, Mass: 47481, Score: 67, Queries matched: 1
Enolase 1 [Homo sapiens]
2N o  s i g n a l
3 gi|110077, Mass: 17476, Score: 59, Queries matched: 1 
Ig gamma-1 chain C region (15C5)-mouse (fragment) 
gi|164318, Score: 87, Queries matched: 1 
Albumin
Immnoprecipitated and separated proteins shown in Fig. 1 were 
eluted and subjected to be further analyzed by Q-Tof analysis as
described in Materials and Methods. 
ing soluble protein fraction in this experiment. It is thought 
that sCM1 account for just a small part of soluble proteins, 
t h e  m a s s  c u l t u r e  o f  R a j i  w a s  p e r f o r m e d  b y  u s i n g  o f  p r o -
tein-free  culture  media.  five  liters  of  culture  supernatants 
were concentrated to hundred microliter of by ultrafiltration. 
Concentrated  supernatants  were  subjected  to  immnopre-
cipitation,  followed  by  electrophoresis  on  10%  SDS-poly-
acrylamide gel and silver staining. As shown in Fig. 1, we 
could  find  3  bands,  which  assumed  to  react  with  anti-CM1 
mAb, at near the region of 46 kDa. Those bands were ex-
tracted and subjected to Q-Tof analysis. One of the protein 
fractions is identical to enolase-1(ENO1), a glycolytic enzyme 
(Table  I).
    Even though ENO1 is expressed in the cytosol and known 
as  a  key  enzyme  in  glycolysis,  there  are  some  reports  that 
ENO1 is expressed on the surface of monocytic leukemia cell 
line, U937 and activated lymphocytes (6,7). Based on this re-
port  and  our  data,  we  confirmed  whether  CM1  is  identical 
molecules with ENO1. First, we examined whether anti-CM1 
mAb could detect recombinant ENO1. Anti-CM1 mAb success-
fully detected recombinant ENO1 (Fig. 2A). In addition, we 
did the competition assay between anti-CM1 mAb and com-
mercially  available  anti-ENO1  mAbs.  Raji  cells  were  treated 
with 0.1μg of anti-ENO1 mAb prior to add 1μg of anti-CM1 
mAbs.  The  binding  activity  of  anti-CM1  mAbs  was  slightly 
decreased. However, its binding activity was more decreased 
by the addition of 0.2μg of anti-ENO1 mAb (Fig. 2B). It as-
sumes that complete inhibition is not shown due to the differ-
ent  affinity  of  both  of  antibodies.  However,  these  data  are 
enough to determine that CM1 is an identical molecule with 
ENO1.
The roles of CM1/ENO1 on the production of pro-
staglandin E2 production
Next, we investigate the function of CM1 on the production 
of prostaglandin E2 (PGE2) from Raji cells, since we have al-
ready found the increase of pro-inflammatory cytokine pro-
duction from Raji cells (data not shown). As shown in Fig. 
3A,  we  found  that  extensive  PGE2  production  by  the  stim-
ulation of CM1 on Raji. It suggests that CM1 plays a role in 
the  pathogenesis  of  several  kinds  of  inflammatory  disease. 
ENO1’s  functions  on  the  pathogenesis  of  inflammatory  dis-
eases  and  autoimmune  diseases  were  already  reported.  To 
confirm whether CM1 is an identical molecule with ENO1 in 
terms  of  its  functional  activity,  changing  on  the  production 
of  PGE2 b y  t h e  t r a n s f e c t i o n  o f  E N O 1  s p e c i f i c  s i R N A  w a s  
examined.  CM1-induced  PGE2  production  from  the  cells 
transfected  with  ENO1  specific  siRNA  was  decreased  in  a 
dose-dependent  manner  (Fig.  3B).  Therefore,  we  can  con-
clude  that  CM1  is  an  identical  molecule  with  ENO1  and 
CM1/ENO1  is  involved  in  the  production  of  one  of  in-The Cloning of CM1
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Figure 2. Determination of CM1
as an identical molecule to 
ENO1. (A) Five micrograms of 
recombinant ENO1 protein was
detected by anti-CM1 mAb. (B) 
Next, we investigated whether 
anti-CM1 mAb and anti-ENO1 
mAb recognize spontaneously 
expressed ENO1 at the same 
time by the flow cytometric 
analysis. The binding capacity 
of anti-CM1 mAb (1μg) was 
gradually decreased by the 
addition of anti-ENO1 mAbs 
(0.1μg and 0.2μg). 
Figure 3. Increase of PGE2 pro-
duction by CM1 stimulation 
and its decreasing by ENO1 
siRNA transfection. (A) Produc-
tion of PGE2 was measure by 
ELISA as described in Materials 
and Methods. Briefly, cells 
were stimulated with anti-CM1
mAbs (1μg/ml) for 1 hr and 
further incubation for another 
24 hrs. The amount of PGE2
produced by CM1 stimulation 
was measured by ELISA. (B) 
PGE2 production from ENO1- 
siRNA transfected Raji cells was
measured, after stimulation with
anti-CM1 mAbs.
flammatory  mediators,  PGE2.
The roles of CM1/ENO1 on the production of MMP- 
2/-9 from stomach cancer
We have previously reported that CM1 is highly expressed 
o n  s e v e r a l  k i n d s  o f  t u m o r  c e l l s  ( 2 ) .  H o w e v e r ,  E N O 1  e x -
pression on tumor is not investigated. So, we examined the 
expression  ENO1  on  the  surfaces  of  stomach  cancer  cell 
line, NCI-N87 with anti-ENO1 mAb and compared it when 
it stained with anti-CM1 mAb. There was a subtle difference 
on the detection of CM1/ENO1 by both of antibodies (Fig. 
4A). As we described above, it might be due to the different 
affinity of both antibodies. It is well-known that matrix met-
alloprotease  (MMP)-2/-9  is  important  factor  for  the  meta-
stasis  of  cancer  through  the  remodeling  of  matrix  around 
tumor.  Therefore,  we  next  examined  the  production  of 
MMP-2/-9  from  NCI-N87  after  ligation  of  ENO1  with  an-
ti-ENO1 mAb. As shown in Fig. 4B, increased MMP-2/-9 ac-
tivity was  shown by  the stimulation  with  anti-ENO1  mAb. 
It suggests that CM1/ENO1 also plays an important role on 
the  metastatic  process  through  the  increase  of  MMP-2/-9 
production  of  stomach  cancer.
DISCUSSION
We have already investigated the function of CM1 on the de-
velopment and differentiation of B cells thought the induction 
of  apoptosis  and  its  related  mechanisms  (1,4).  However,  it The Cloning of CM1
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Figure 4. Expression of CM1/ENO1 on NCI-N87 and its role on the
induction of MMP-2/-9 production. (A) The expression of CM1/ENO1
was examined by anti-CM1 mAb and anti-ENO1 mAb, respectably. 
Cells were incubated with FITC-conjugated anti-CM1 mAbs or 
anti-ENO1 mAbs and acquired on an FACS Calibur. (B) The increase
of MMP-2/-9 production by the stimulation of anti-ENO1 mAb. To 
examine the activity of matrix gelatinases (MMP-2 and MMP-9), 
NCI-N87 was incubated with anti-ENO1 mAb. Digested regions are 
shown as white bands on a background.
was  very  difficult  to  explain  its  importance  on  the  patho-
g e ne si s,  si nc e  th e  id en t it y o f C M 1 w as  no t  cl ea rly  d ef in ed . 
Even though we tried to establish the identity of CM1 via the 
several  kinds  of  molecular  and  cellular  methods,  we  could 
not clearly defined due to the CM1 is inducible molecules un-
der inflammatory and pathogenic condition. Moreover, it ex-
ists as a low abundance protein among membrane proteins.
  In this experiment, we figured out the determination of the 
identity of CM1, based on its existence as a soluble form. We 
used Q-Tof analysis, because the most important factors for 
the  identification  of  low-level  of  impurities  and  low  abun-
dance proteins is sensitivity and dynamic ranges for analysis 
(8,9).  Q-Tof  analysis  is  more  confidence  analysis  for  low 
abundance proteins and low molecular weight compounds. 
Finally,  we  succeeded  to  determine  the  identity  of  CM1  as 
α-enolase  (ENO1).
    ENO1 is one of the isotype of enolase family and others 
are β-enolase (ENO3) and γ-enolase (ENO2). Even though 
ENO1 is a key enzyme for glycolysis, there are several reports 
regarding  the  role  of  ENO1  in  inflammatory  responses  and 
autoimmune diseases (10). Especially, the roles of ENO1 on 
the  development  and  pathogenesis  of  rheumatoid  arthritis 
(RA) and systemic lupus erythematosus (SLE) are well inves-
tigated (11-13). Expression pattern of ENO1 seems to show 
disease specific patterns. It  suggests that  ENO1  might  be a 
target for the control of such kinds of diseases. In fact, we 
already observed that the symptoms and disease progression 
of RA have gotten better after regulation of ENO1 activity by 
anti-ENO1 mAbs or specific inhibitors for ENO1 function (our 
unpublished data). The roles of ENO1 mostly rely on its 1) 
immunogenic  properties,  2)  DNA-binding  ability,  and  3) 
Plasminogen  receptor  function.  However,  the  specific  role 
and  function  of  ENO1  regarding  the  pathogenesis  of  auto-
i m m u n e  d i s e a s e s  r e m a i n  t o  b e  c l a r i f i e d .
  A p a r t  f r o m  a u t o i m m u n e  d i s e a s e s ,  t h e  r e c e n t  r e s e a r c h  r e-
garding the roles of ENO1 are focused at cancers, infections 
and ischemia (10). Even though the data is not presented in 
this  reports,  we  found  the  expression  of  ENO1  on  several 
types  of  tumor  cells  including,  stomach  cancer,  hepatoma, 
lung cancer, breast cancer, and prostate cancer. It seems that 
the expression of ENO1 is closely related with the malignancy 
of cancer cells, since higher expression on tumor shown high 
metastatic ability than cells showing non-metastatic ability was 
observed. As we shown in Fig. 4A, ENO1 expression is highly 
expressed on NCI-N87, stomach cancer cell line that shows 
prominent malignancy with high metastatic ability. In addi-
tion,  ENO1  is  also  involved  in  the  metastasis  of  cancer 
through  the  increase  of  MMP-2/-9  production.  In  fact,  we 
f o u n d  t h a t  t h e  i n c r e a s e  o f  C M 1  ( t h e  n a m e  o f  E N O 1  c a l l e d 
before  determination)  production and expression in the  se-
rum  and  tissues  of  stomach  cancer  patients.
    As we described shortly above, plasminogen is known as 
a  ligand  for  membrane  expressed  ENO1  in  vivo  (14,15).  It 
means  that  the  inflammatory  responses  and  MMP-2/-9  pro-
duction can be actually triggered by plasminogen through the 
stimulation ENO1 on inflammatory mediator cells and cancer 
cells, respectively, even though we showed here by using of 
anti-ENO1  mAbs.  However,  we  do  not exclude  the role  of 
anti-ENO1 mAbs in vivo, especially on the development and 
pathogenesis of autoimmune diseases, since there are several 
reports  regarding  the  increase  of  serum  titer  of  anti-ENO1 
mAbs in autoimmune disease patients. The serum levels of 
anti-ENO1  mAbs  in  cancer  patients  are  now  under  inves-
tigation. Taken together, CM1/ENO1 might be a useful target 
for the therapy of autoimmune diseases and cancer through 
the  development  of  anti-CM1(ENO1)  antibody-based  ther-
apeutic  reagents  and  appropriate  inhibitors  for  function  of 
membrane  CM1/ENO1. 
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